Market Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced the presentation of results from a multi-arm Phase 2 clinical trial evaluating grazoprevir/elbasvir with or without ribavirin . . . → Read More: Market Update: Merck & Co Inc (NYSE:MRK) – Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Naïve and Difficult-to-Cure Patients Similar Articles: Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients Company Update (NYSE:MRK): Merck Announces Third-Quarter 2014 Dividend Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C